OR WAIT null SECS
July 25, 2023
The damage to the facility, which produces 8% of US injectable drug consumption, should not significantly affect the current supply.
July 24, 2023
The framework is now expanded beyond COVID-19 vaccines and treatments.
The paper highlights the potential of AI in the medicinal product lifecycle and the approach that developers should take with it.
Sanofi and Recludix Pharma’s deal centers on developing treatments for various immunological and inflammatory diseases.
WuXi STA’s new high-potency injectable line has an annual capacity of 12 million units.
Newly launched Crossbow Therapeutics will work to advance a novel class of antibody therapies for treating cancers.
July 21, 2023
Under a global license agreement, Bristol Myers Squibb and Evotec will advance the development of neurodegeneration pipeline assets.
The proposed spin-off of Sandoz into an independent entity has been approved by Novartis’ board of directors.
The partnership will see Flagship and Pfizer work to create a new pipeline of innovative medicines.
The expanded deal, now potentially worth more than $1.2 billion, will work to develop in vivo therapies, including sickle cell disease.